Formulation Development
Product Description
Alcami
-
US
-
2016On CPHI since
-
1000 - 4999Employees
Company types
Categories
Alcami
-
US
-
2016On CPHI since
-
1000 - 4999Employees
Company types
More Products from Alcami (17)
-
Product Stability
Study Types-In-use studies (broaching, reconstituted product stability, multi-use container stability)
-Formulation development studies including stress studies
-Photostability (Options I and II)
-Comparator studies
-Thermal cycling/freeze thaw
-Shipping excursion studies
-Long-term stabi... -
Product Analytical Services
Method development and phase appropriate validations to support clinical and commercial programsCompendial Testing
Raw Material Testing -
Product Contract Manufacturing
Development and optimization of suitable manufacturing processes to support clinical and commercial programs -
Product Contract Packaging
Support stand along packaging activities or integrated with Alcami's manufacturing capabilities. Can support packaging for clinical kits including kit assembly and commercial packaging. -
Product Extractable and Leachable Studies
Alcami’s expertise includes the assessment of a broad variety of drug products, routes of administration, and manufacturing system components. A proper assessment includes studies to not only understand which compounds have the ability to leach into the drug product, but also studies to identify which comp... -
Product Fill / Finish Services
Fill / Finish services to support biologics. -
Product Lyophilization
Developing and optimizing lyo cycles to support clinical and commercial programs -
Product Tech Transfer and Scale Up
Tech Transfer and Scale up to support clinical and commercial programs -
Product Analytical development
Alcami offers a fully-integrated analytical method development, method validation, and testing solution with a full complement of advanced analytical and information technologies. From Alcami’s electronic laboratory notebook (ELN) data collection system to its integration with our formulation development, ... -
Product Biopharmaceutical development
From initial characterization of drug substance to commercial batch release, each phase of your drug product development requires analytical methods to qualify the product for safety, integrity, strength, purity, and quality. With these critical attributes in mind, Alcami’s biologics analytical devel... -
Product Formulation development
Alcami’s formulation development team proactively guides your development program every step of the way – from Compound to Clinic. Our team is adept at solving challenging formulations for new chemical entities (NCEs) and developing high-performance dose forms to meet today’s consumer needs. We offer... -
Product Integrated offerings
Alcami is a Us-based, contract development, testing, and manufacturing organization for pharma and biotech companies. Our goal is to support our clients in making their projects go from potential to reality day-after-day.
Core Capabilities:Sterile-fill finish development and manufacturingO...
Alcami resources (3)
-
News Alcami to manufacture PharmaTher’s proprietary ketamine products
The CDMO will supply expertise in GMP sterile fill-finish manufacturing and controlled-substances -
Brochure Food Studies Brochure
Alcami is equipped and ready to handle study design and execution of food studies to support a variety of oral solid dosage forms, including tablets, capsules, and suspensions. Our subject matter experts have developed and executed studies using infant formula, yogurt, orange juice, apple sauce, smoothies, and a variety of other foods and drinks. -
Webinar Expanding the OSD Toolbox with an Industry-Based Approach to Lipid and Surfactant Adsorption onto Dry Powder Excipients to Increase the Dissolution Rate of BCS Class II and Class IV Active Pharmaceutical Ingredients (API’s)
Common high-performance lipids and surfactants were used to improve the dissolution rate of furosemide as a model compound for BCS Class II and Class IV active pharmaceutical ingredients. Furosemide equilibrium solubility was measured throughout an HLB range (1-16) of liquid lipids and surfactants. Furosemide tablets were then manufactured using high shear granulation to absorb the solubilized and suspended furosemide onto microcrystalline cellulose (Avicel PH101). The granulations were then compressed using a rotary tablet press and standard tablet tooling. Finished tablets were analyzed to compare dissolution rates using 0.1 N HCl media and USP Apparatus II. Higher equilibrium solubility yielded increased dissolution rates for furosemide tablets compared to directly compressed furosemide tablets.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance